Fintel reports that on August 31, 2023, Cantor Fitzgerald reiterated coverage of Portage Biotech (NASDAQ:PRTG) with a Overweight recommendation.
Analyst Price Forecast Suggests 279.18% Upside
As of August 31, 2023, the average one-year price target for Portage Biotech is 10.20. The forecasts range from a low of 9.09 to a high of $11.55. The average price target represents an increase of 279.18% from its latest reported closing price of 2.69.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Portage Biotech is 0MM. The projected annual non-GAAP EPS is -1.04.
What is the Fund Sentiment?
There are 28 funds or institutions reporting positions in Portage Biotech. This is a decrease of 1 owner(s) or 3.45% in the last quarter. Average portfolio weight of all funds dedicated to PRTG is 0.01%, an increase of 613.59%. Total shares owned by institutions increased in the last three months by 98.48% to 367K shares.
What are Other Shareholders Doing?
Lakeview Capital Partners holds 213K shares representing 1.20% ownership of the company.
IWC - iShares Micro-Cap ETF holds 23K shares representing 0.13% ownership of the company. In it's prior filing, the firm reported owning 22K shares, representing an increase of 5.04%. The firm increased its portfolio allocation in PRTG by 15.82% over the last quarter.
Citadel Advisors holds 19K shares representing 0.11% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
Ieq Capital holds 17K shares representing 0.09% ownership of the company.
Sigma Planning holds 12K shares representing 0.06% ownership of the company. No change in the last quarter.
Portage Biotech Background Information
(This description is provided by the company.)
Portage Biotech Inc. is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.
Additional reading:
- Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update Company focused on accelerating clinical programs for PORT-2, PORT-6, and PORT-7
- The accompanying notes are an integral part of these condensed consolidated interim financial statements.
- PORTAGE BIOTECH INC. THREE MONTHS ENDED JUNE 30, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of August 29, 2023
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
